Comparative Pharmacology
Head-to-head clinical analysis: ENZALUTAMIDE versus NUBEQA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENZALUTAMIDE versus NUBEQA.
ENZALUTAMIDE vs NUBEQA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor inhibitor; binds to the androgen receptor and inhibits androgen receptor nuclear translocation, DNA binding, and coactivator recruitment.
Androgen receptor inhibitor; binds to the androgen receptor and inhibits nuclear translocation, DNA binding, and recruitment of coactivators, thereby reducing prostate cancer cell proliferation.
160 mg orally once daily
600 mg orally twice daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 5.8 days (range 2.8–10.2 days) after steady state; supports once-daily dosing.
Clinical Note
moderateEnzalutamide + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Enzalutamide."
Clinical Note
moderateEnzalutamide + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Enzalutamide."
Clinical Note
moderateEnzalutamide + Deslanoside
"Enzalutamide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateEnzalutamide + Acetyldigitoxin
Terminal elimination half-life is approximately 20 hours; supports once-daily dosing.
Primarily hepatic metabolism; ~70% of dose excreted in feces (as unchanged drug and metabolites), ~1% in urine as unchanged drug. Biliary excretion is a major route.
Primarily excreted as unchanged drug via feces (approximately 63.7%) and urine (approximately 23.8%); minimal biliary excretion.
Category D/X
Category C
Androgen Receptor Inhibitor
Androgen Receptor Inhibitor
"Enzalutamide may decrease the cardiotoxic activities of Acetyldigitoxin."